TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Charles River Labs ( (CRL) ) is now available.
On May 16, 2023, Charles River Laboratories received an inquiry from the SEC’s Enforcement Division regarding the sourcing of non-human primates, which led to an independent investigation by the company’s Audit Committee. On November 14, 2025, the SEC concluded its investigation without recommending enforcement action, and the company’s independent investigation also found no material issues.
The most recent analyst rating on (CRL) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.
Spark’s Take on CRL Stock
According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.
Charles River Labs exhibits strong revenue growth and cash flow generation, but faces significant profitability challenges. Technical indicators show positive momentum, but valuation metrics are concerning due to negative earnings. The earnings call highlighted strategic initiatives but also revealed ongoing operational challenges.
To see Spark’s full report on CRL stock, click here.
More about Charles River Labs
Charles River Laboratories International, Inc. operates in the life sciences industry, providing essential products and services for drug discovery and development. The company focuses on offering research models and associated services to support pharmaceutical and biotechnology companies in their research endeavors.
Average Trading Volume: 991,550
Technical Sentiment Signal: Hold
Current Market Cap: $8.26B
For a thorough assessment of CRL stock, go to TipRanks’ Stock Analysis page.